INM · InMed Pharmaceuticals Inc
United States · RS rating 57 · As of 2026-10-14
| Price | 1.31 USD |
|---|---|
| 1-day change | -1.5% |
| RS rating (overall / 1M / 3M / 12M) | 57 / 82 / 22 / 18 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 26 / 26 / 38 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | -15.9% |
| Sales growth Q/Q | -26.8% |
| Distance from 52-week high | +40.5% |
| Market cap (USD) | $2.5M |